Table 3. Performance of MS-HRM assays.
| ID | Cutoff Value | Normal Lung |
Lung Tumor |
Sensitivity | Specificity | ||||
|---|---|---|---|---|---|---|---|---|---|
| Methylation Level | True Negative n (%) | False positive n (%) | N (%) | False Negative n (%) | True Positive n (%) | N (%) | |||
| OSR1 | >1% | 30 (96.8) | 1 (3.2) | 31 (100) | 1 (2.1) | 47 (97.9) | 48 (100) | 0.98 | 0.97 |
| SIM1 | >1% | 28 (90.3) | 3 (9.7) | 31 (100) | 4 (8.2) | 45 (91.8) | 49 (100) | 0.92 | 0.90 |
| HOXD10 | >1% | 26 (81.3) | 6 (18.7) | 32 (100) | 5 (9.8) | 46 (90.2) | 51 (100) | 0.90 | 0.81 |
| HIST1H3E | >50% | 29 (90.6) | 3 (9.4) | 32 (100) | 5 (10.0) | 45 (90.0) | 50 (100) | 0.90 | 0.91 |
| HOXD3 | >10% | 30 (96.8) | 1 (3.2) | 31 (100) | 7 (14.0) | 43 (86.0) | 50 (100) | 0.86 | 0.97 |
| GHSR | >10% | 30 (96.8) | 1 (3.2) | 31 (100) | 8 (16.7) | 40 (83.3) | 48 (100) | 0.83 | 0.97 |
| Chr1(q21.1).A | >10% | 30 (100) | 0 (0) | 30 (100) | 10 (20.8) | 38 (79.2) | 48 (100) | 0.79 | 1.00 |
| HOXB3/HOXB4 | >1% | 31 (100) | 0 (0) | 31 (100) | 12 (25.0) | 36 (75.0) | 48 (100) | 0.75 | 1.00 |
| Chr6(p22.1) | >1% | 32 (100) | 0 (0) | 32 (100) | 16 (32.6) | 33 (67.4) | 49 (100) | 0.67 | 1.00 |
| HIST1H3G/HIST1H2BI | >1% | 32 (100) | 0 (0) | 32 (100) | 19 (36.5) | 33 (63.5) | 52 (100) | 0.63 | 1.00 |
| OTX2 | >1% | 31 (100) | 0 (0) | 31 (100) | 25 (49.0) | 26 (51.0) | 51 (100) | 0.51 | 1.00 |
| LOC648987 | >1% | 29 (100) | 0 (0) | 29 (100) | 34 (75.5) | 11 (24.5) | 45 (100) | 0.24 | 1.00 |
| HIST1H2AJ/HIST1H2BM | >1% | 32 (100) | 0 (0) | 32 (100) | 40 (78.4) | 11 (21.6) | 51 (100) | 0.22 | 1.00 |
| HOXA3 | >50% | 29 (100) | 0 (0) | 29 (100) | 43 (86.0) | 7 (14.0) | 50 (100) | 0.14 | 1.00 |
| HOXA5 | >50% | 31 (100) | 0 (0) | 31 (100) | 46 (88.4) | 6 (11.6) | 52 (100) | 0.12 | 1.00 |